Review of the international clinical practice guidelines for the treatment of lung infections caused by nontuberculous mycobacteria

A.V.  Zhestkov; V. Lyamin Artem; D.D.  Ismatullin; A.A.  Martinovich; E.V.  Haykina

doi:10.36488/cmac.2021.1.66-91

1. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. DOI: 10.1164/rccm.200604-571

2. Marras T.K., Mendelson D., Marchand-Austin A., May K., Jamieson F.B. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19:1889-1891. DOI: 10.3201/eid1911.130737

3. Adjemian J., Olivier K.N., Seitz A.E., Holland S.M., Prevots D.R. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881-886. DOI: 10.1164/rccm.201111-2016OC

4. Prevots D.R., Marras T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13-34. DOI: 10.1016/j.ccm.2014.10.002

5. Henkle E., Hedberg K., Schafer S., Novosad S., Winthrop K.L. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc. 2015;12:642-647. DOI: 10.1513/AnnalsATS.201412-559OC

6. van Ingen J., Hoefsloot W., Dekhuijzen P.N., Boeree M.J., van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010;14:1176-1180. PMID: 20819265

7. Anisimova A.I., Pavlova M.V., Archakova L.I., Sapozhnikova N.V., Chernokhaev I.V., Gavrilov P.V., et al. Mikobacteriosis of the lungs: difficulties of diagnosis and treatment. Medicinskij al'jans. Russian. DOI: 10.36422/23076348-2020-8-1-25-31

8. Zimina V.N., Degtyareva S.Yu., Beloborodova E.N., Kulabukhova E.I., Rusakova L.I., Fesenko O.V. Mikobacteriosis: the modern state of the problem. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(4):276-282. Russian.

9. Karpina N.L., Asanov R.B., Shishkina E.R., Larionova E.E., Shabalina I.Yu., Ergeshov A.E. Clinical and microbiological aspects of the diagnosis of nontuberculous mycobacterioses in cavity formations in the lungs. Bulletin of the Central Tuberculosis Research Institute. 2020;4:73-80. Russian. DOI: 10.7868/S2587667820040081

10. van Ingen J., Turenne C.Y., Tortoli E., Wallace R.J. Jr., Brown-Elliott B.A. A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. Int J Syst Evol Microbiol. 2018;68:3666-3677. DOI: 10.1099/ijsem.0.003026

11. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest. 1991;99:667-669. DOI: 10.1378/chest.99.3.667

12. Koh W.J., Chang B., Ko Y., Jeong B.-H., Hong G., Park H.Y., et al. Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. Diagn Microbiol Infect Dis. 2013;75:225-226. DOI: 10.1016/j.diagmicrobio.2012.09.021

13. Lee M.R., Yang C.Y., Shu C.C., Lin C.-K., Wen Y.-F., Lee S.-W., et al. Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination. Clin Microbiol Infect. 2015;21:250.e1-7. DOI: 10.1016/j.cmi.2014.08.025

14. van Ingen J., Bendien S.A., de Lange W.C., Hoefsloot W., Dekhuijzen P., Boeree M.J., et al. Clinical relevance of nontuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64:502-506. DOI: 10.1136/thx.2008.110957

15. Jankovic M., Sabol I., Zmak L., Katalinic Jankovic V., Jakopovic M., Obrovac M., et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016; 20:934-940. DOI: 10.5588/ijtld.15.0633

16. van Ingen J., Boeree M.J., van Soolingen D., Iseman M.D., Heifets L.B., Daley C.L. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol. 2012;12:832837. DOI: 10.1016/j.meegid.2011.10.006

17. Sugihara E., Hirota N., Niizeki T., Tanaka R., Nagafuchi M., Koyanagi T., et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother. 2003;9:328-332. DOI: 10.1007/s10156003-0267-1

18. Tanaka E., Amitani R., Niimi A., Suzuki K., Murayama T., Kuze F. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1997;155:20412046. DOI: 10.1164/ajrccm.155.6.9196113

19. Huang J.H., Kao P.N., Adi V., Ruoss S.J. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999;115:1033-1140. DOI: 10.1378/chest.115.4.1033

20. Watanuki Y., Odagiri S., Suzuki K., Takahashi H., Takahashi K., Yoshiike Y., et al. Usefulness of bronchoscopy for the diagnosis of atypical pulmonary mycobacteriosis. Kansenshogaku Zasshi. 1999;73:728-733. DOI: 10.11150/kansenshogakuzasshi1970.73.728

21. Ikedo Y. The significance of bronchoscopy for the diagnosis of Mycobacterium avium complex (MAC) pulmonary disease. Kurume Med. J 2001;48:15-19. DOI: 10.2739/kurumemedj.48.15

22. Peres R.L., Maciel E.L., Morais C.G., Ribeiro F., Vinhas S., Pinheiro C., et al. Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. Int J Tuberc Lung Dis. 2009;13:15721575. PMID: 19919781

23. Cruciani M., Scarparo C., Malena M., Bosco O., Serpelloni G., Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42:2321-2325. DOI: 10.1128/JCM.42.5.23212325.2004

24. Chew W.K., Lasaitis R.M., Schio F.A., Gilbert G.L. Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species. J Med Microbiol. 1998;47:821-827. DOI: 10.1099/00222615-47-9-821

25. Idigoras P., Beristain X., Iturzaeta A., Vicente D., PérezTrallero E. Comparison of the automated nonradiometric Bactec MGIT 960 system with Löwenstein-Jensen, Coletsos, and Middlebrook 7H11 solid media for recovery of mycobacteria. Eur J Clin Microbiol Infect Dis. 2000;19:350354. DOI: 10.1007/s100960050492

26. Sorlozano A., Soria I., Roman J., Huertas P., Soto M.J., Piedrola G., et al. Comparative evaluation of three culture methods for the isolation of mycobacteria from clinical samples. J Microbiol Biotechnol. 2009;19:1259-1264. DOI: 10.4014/jmb.0901.0059

27. Rivera A.B., Tupasi T.E., Grimaldo E.R., Cardano R.C., Co V.M. Rapid and improved recovery rate of Mycobacterium tuberculosis in mycobacteria growth indicator tube combined with solid Löwenstein Jensen medium. Int J Tuberc Lung Dis. 1997;1:454-459. PMID: 9441101

28. Alcaide F., Benítez M.A., Escribà J.M., Martín R. Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe. J Clin Microbiol. 2000;38:398-401. PMID: 10618124

29. Lu D., Heeren B., Dunne W.M. Comparison of the automated mycobacteria growth indicator tube system (BACTEC 960/MGIT) with Löwenstein-Jensen medium for recovery of mycobacteria from clinical specimens. Am J Clin Pathol. 2002;118:542-545. DOI: 10.1309/65KN2M7E-7MNN-X0TA

30. Lee J.J., Suo J., Lin C.B., Wang J.D., Lin T.Y., Tsai Y.C. Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis. 2003;7:569-574. PMID: 12797700

31. Hillemann D., Richter E., Rüsch-Gerdes S. Use of the BACTEC mycobacteria growth indicator tube 960 automated system for recovery of mycobacteria from 9,558 extrapulmonary specimens, including urine samples. J Clin Microbiol. 2006;44:4014-4017. DOI: 10.1128/JCM.00829-06

32. CLSI. Laboratory detection and identification of mycobacteria. 2nd ed. Vol. M48. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.

33. Alfa M.J., Manickam K., Sepehri S., Sitter D., Lenton P. Evaluation of BacT/Alert 3D automated unit for detection of nontuberculous mycobacteria requiring incubation at 30 degrees C for optimal growth. J Clin Microbiol. 2011;49:2691-2693. DOI: 10.1128/JCM.00513-11

34. Peter-Getzlaff S., Lüthy J., Voit A., Bloemberg G.V., Böttger E.C. Detection and identification of Mycobacterium spp. in clinical specimens by combining the Roche Cobas amplicor Mycobacterium tuberculosis assay with Mycobacterium genus detection and nucleic acid sequencing. J Clin Microbiol. 2010;48:3943-3948. DOI: 10.1128/JCM.00851-10

35. Deggim-Messmer V., Bloemberg G.V., Ritter C., Voit A., Hömke R., Keller P.M., et al. Diagnostic molecular mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple mycobacterial pathogens with line probe assays for identification of resistance mutations. EBioMedicine. 2016;9:228-237. DOI: 10.1016/j.ebiom.2016.06.016

36. van Ingen J., de Zwaan R., Enaimi M., Dekhuijzen P.N., Boeree M.J., van Soolingen D. Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999-2007. Clin Microbiol Infect. 2010;16:1470-1474. DOI: 10.1111/j.1469-0691.2009.03127.x

37. Tortoli E., Pecorari M., Fabio G., Messinò M., Fabio A. Commercial DNA probes for mycobacteria incorrectly identify a number of less frequently encountered species. J Clin Microbiol. 2010;48:307-310. DOI: 10.1128/JCM.01536-09

38. McNabb A., Eisler D., Adie K., Amos M., Rodrigues M., Stephens G., et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol. 2004;42:3000-3011. DOI: 10.1128/JCM.42.7.3000-3011.2004

39. Adékambi T., Colson P., Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003;41:56995708. DOI: 10.1128/jcm.41.12.5699-5708.2003

40. de Zwaan R., van Ingen J., van Soolingen D. Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands. J Clin Microbiol. 2014;52:2544-2551. DOI: 10.1128/JCM.00233-14

41. Roth A., Fischer M., Hamid M.E., Michalke S., Ludwig W., Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. J Clin Microbiol. 1998;36:139-147. PMID: 9431937

42. van Ingen J., Hoefsloot W., Buijtels P.C., Tortoli E., Supply P., Dekhuijzen P.N.R., et al. Characterization of a novel variant of Mycobacterium chimaera. J Med Microbiol. 2012;61:1234-1239. DOI: 10.1099/jmm.0.045070-0

43. Macheras E., Roux A.L., Bastian S., Leão S.C., Palaci M., Sivadon-Tardy V., et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol. 2011;49:491-499. DOI: 10.1128/JCM.01274-10

44. Zelazny A.M., Root J.M., Shea Y.R., Colombo R.E., Shamputa I.C., Stock F., et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol. 2009;47:1985-1995. DOI: 10.1128/JCM.01688-08

45. Alcaide F., Amlerová J., Bou G., Ceyssens P.J., Coll P., Corcoran D., et al.; European Study Group on Genomics and Molecular Diagnosis (ESGMD). How to: identify nontuberculous Mycobacterium species using MALDI-TOF mass spectrometry. Clin Microbiol Infect. 2018;24:599-603. DOI: 10.1016/j.cmi.2017.11.012

46. Buchan B.W., Riebe K.M., Timke M., Kostrzewa M., Ledeboer N.A. Comparison of MALDI-TOF MS with HPLC and nucleic acid sequencing for the identification of Mycobacterium species in cultures using solid medium and broth. Am J Clin Pathol. 2014;141:25-34. DOI: 10.1309/AJCPBPUBUDEW2OAG

47. Leyer C., Gregorowicz G., Mougari F., Raskine L., Cambau E., de Briel D. Comparison of Saramis 4.12 and IVD 3.0 Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria from solid and liquid culture media. J Clin Microbiol. 2017;55:2045-2054. DOI: 10.1128/JCM.00006-17

48. van Eck K., Faro D., Wattenberg M., de Jong A., Kuipers S., van Ingen J. Matrix-assisted laser desorption ionization-time of flight mass spectrometry fails to identify nontuberculous mycobacteria from primary cultures of respiratory samples. J Clin Microbiol. 2016;54:1915-1917. DOI: 10.1128/JCM.00304-16

49. CLSI. Susceptibility testing of mycobacteria, Nocardia spp, and other aerobic Actinomyces. 3rd ed. Vol. M24. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.

50. CLSI. Performance standards for susceptibility testing of mycobacteria, Nocardia spp, and other aerobic Actinonmyces. 1st ed. Vol. M62. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.

51. Wallace R.J. Jr., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med. 1996;153:1766-1772. DOI: 10.1164/ajrccm.153.6.8665032

52. Tanaka E., Kimoto T., Tsuyuguchi K., Watanabe I., Matsumoto H., Niimi A., et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866-872. DOI: 10.1164/ajrccm.160.3.9811086

53. Meier A., Heifets L., Wallace R.J. Jr., Zhang Y., Brown B.A., Sander P., et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis. 1996;174:354-360. DOI: 10.1093/infdis/174.2.354

54. Meier A., Kirschner P., Springer B., Steingrube V.A., Brown B.A., Wallace V.A. Jr., et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 1994;38:381-384. DOI: 10.1128/aac.38.2.381

55. Brown-Elliott B.A., Iakhiaeva E., Griffith D.E., Woods G.L., Stout J.E., Wolfe C.R., et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51:3389-3394. DOI: 10.1128/JCM.01612-13

56. Griffith D.E., Eagle G., Thomson R., Aksamit T.R., Hasegawa N., Morimoto K., et al.; CONVERT Study Group. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). a prospective, openlabel, randomized study. Am J Respir Crit Care Med. 2018;198:1559-1569. DOI: 10.1164/rccm.2018071318OC

57. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard -2nd edition. CLSI document M24-A2. Wayne, Pennsylvania: Clinical Laboratory Standards Institute, 2011.

58. Jeon K., Kwon O.J, Lee N.Y., Kim B.-J., Kook Y.-H., Lee S.-H., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896-902. DOI: 10.1164/rccm.200905-0704OC

59. Jarand J., Levin A., Zhang L., Huitt G., Mitchell J.D., Daley C.L. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565-571. DOI: 10.1093/cid/ciq237

60. Huang Y.C., Liu M.F., Shen G.H., Lin C.-F., Kao C.-C., Liu P.-Y., et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect. 2010;43:401-406. DOI: 10.1016/S1684-1182(10)60063-1

61. van Ingen J., Totten S.E., Helstrom N.K., Heifets L.B., Boeree M.J., Daley C.L. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56:63246327. DOI: 10.1128/AAC.01505-12

62. Ferro B.E., Meletiadis J., Wattenberg M., de Jong A., van Soolingen D., Mouton J., et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother. 2016;60:1097-1105. DOI: 10.1128/AAC.02615-15

63. Nash K.A., Brown-Elliott B.A., Wallace R.J. Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367-1376. DOI: 10.1128/AAC.01275-08

64. Bastian S., Veziris N., Roux A.L., Brossier F., Gaillard J.-L., Jarlier V., et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother. 2011;55:775-781. DOI: 10.1128/AAC.00861-10

65. Wallace R.J. Jr., Meier A., Brown B.A., Zhang Y., Sander P., Onyi G.O., et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676-1681. PMID: 8807061

66. Hwang J.A., Kim S., Jo K.W., Shim T.S. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49:1600537. DOI: 10.1183/13993003.00537-2016

67. Lee G., Lee K.S., Moon J.W., Koh W.-J., Jeong B.-H., Jeong Y.J., et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. Ann Am Thorac Soc. 2013;10:299-306. DOI: 10.1513/AnnalsATS.201303062OC

68. Gochi M., Takayanagi N., Kanauchi T., Ishiguro T., Yanagisawa T., Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5:e008058. DOI: 10.1136/bmjopen-2015-008058

69. Hayashi M., Takayanagi N., Kanauchi T., Miyahara Y., Yanagisawa T., Sugita Y. Prognostic factors of 634 HIVnegative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185:575-583. DOI: 10.1164/rccm.201107-1203OC

70. Kitada S., Uenami T., Yoshimura K., Tateishi Y., Miki K., Miki M., et al. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Int J Tuberc Lung Dis. 2012;16:660-664. DOI: 10.5588/ijtld.11.0534

71. Koh W.J., Moon S.M., Kim S.Y., Woo M.-A., Kim S., Jhun B.W., et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50:1602503. DOI: 10.1183/13993003.025032016

72. Koh W.J., Jeong B.H., Kim S.Y., Jeon K., Park K.U., Jhun B.W., et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017;64:309-316. DOI: 10.1093/cid/ciw724

73. Wallace R.J. Jr., Zhang Y., Brown-Elliott B.A., Yakrus M.A., Wilson R.W., Mann L., et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis. 2002;186:266-273. DOI: 10.1086/341207

74. Brown-Elliott B.A., Nash K.A., Wallace R.J. Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25:545-582. DOI: 10.1128/CMR.05030-11

75. van Ingen J., Boeree M.J., van Soolingen D., Mouton J.W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15:149-161. DOI: 10.1016/j.drup.2012.04.001

76. Olivier K.N., Griffith D.E., Eagle G., McGinnis J.P. 2nd, Micioni L., Liu K., et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814823. DOI: 10.1164/rccm.201604-0700OC

77. Chaisson R.E., Benson C.A., Dube M.P., Heifets L.B., Korvick J.A., Elkin S., et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994;121:905-911. DOI: 10.7326/0003-4819-121-12-199412150-00001

78. Wallace R.J. Jr., Dunbar D., Brown B.A., Onyi G., Dunlap R., Ahn C.H., et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18:736-743. DOI: 10.1093/clinids/18.5.736

79. Ahn C.H., Wallace R.J. Jr., Steele L.C., Murphy D.T. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis. 1987;135:10-16. DOI: 10.1164/arrd.1987.135.1.10

80. Griffith D.E., Brown-Elliott B.A., Langsjoen B., Zhang Y., Pan X., Girard W., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174:928-934. DOI: 10.1164/rccm.200603-450OC

81. Kobashi Y., Yoshida K., Miyashita N., Niki Y., Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12:195-202. DOI: 10.1007/s10156-011-0351-x

82. Koh W.J., Jeon K., Lee N.Y., Kim B.-J., Kook Y.-H., Lee S.-H., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183:405-410. DOI: 10.1164/rccm.201003-0395OC

83. Mougari F., Amarsy R., Veziris N., Bastian S., Brossier F., Berçot B., et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother. 2016;71:22082212. DOI: 10.1093/jac/dkw130

84. Dautzenberg B., Truffot C., Legris S., Meyohas M.C., Berlie H.C., Mercat A., et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis. 1991;144:564-569. DOI: 10.1164/ajrccm/144.3_Pt_1.564

85. Pierce M., Crampton S., Henry D., Heifets L., LaMarca A., Montecalvo M., et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384391. DOI: 10.1056/NEJM199608083350603

86. Havlir D.V., Dubé M.P., Sattler F.R., Forthal D.N., Kemper C.A., Dunne M.W., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392-398. DOI: 10.1056/NEJM199608083350604

87. Shafran S.D., Singer J., Zarowny D.P., Phillips P., Salit I., Walmsley S., et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med. 1996;335:377-383. DOI: 10.1056/NEJM199608083350602

88. Benson C.A., Williams P.L., Currier J.S., Holland F., Mahon L.F., MacGregor R.R., et al.; AIDS Clinical Trials Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:1234-1243. DOI: 10.1086/378807

89. Field S.K., Fisher D., Cowie R.L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004;126:566-581. DOI: 10.1378/chest.126.2.566

90. Kadota J.I., Kurashima A., Suzuki K. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: a nationwide post-marketing study. J Infect Chemother. 2017;23:293-300. DOI: 10.1016/j.jiac.2017.01.007

91. Yeates R.A., Laufen H., Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther. 1996;34:400405. PMID: 8880291

92. Schembri S., Williamson P.A., Short P.M., Singanayagam A., Akram A., Taylor J., et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. DOI: 10.1136/bmj.f1235

93. Gluud C., Als-Nielsen B., Damgaard M., Hansen J.F., Hansen S., Helø O.H., et al.; CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology. 2008;111:280-287. DOI: 10.1159/000128994

94. Hansen M.P., Scott A.M., McCullough A., Thorning S., Aronson J.K., Beller E.M., et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1:CD011825. DOI: 10.1002/14651858.CD011825.pub2

95. Brown B.A., Griffith D.E., Girard W., Levin J., Wallace R.J. Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis. 1997;24:958-964. DOI: 10.1093/clinids/24.5.958

96. Wallace R.J. Jr., Brown B.A., Griffith D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993;16:215-221. DOI: 10.1016/0732-8893(93)90112-k

97. Griffith D.E., Brown B.A., Girard W.M., Murphy D.T., Wallace R.J. Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:983-989. DOI: 10.1093/clinids/23.5.983

98. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Am J Respir Crit Care Med. 1997;156(2 Pt. 2):S1-S25. DOI: 10.1164/ajrccm.156.2.atsstatement

99. Kobashi Y., Matsushima T., Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130-138. DOI: 10.1016/j.rmed.2006.04.002

100. Morimoto K., Namkoong H., Hasegawa N., Nakagawa T., Morino E., Shiraishi Y., et al.; Nontuberculous Mycobacteriosis Japan Research Consortium. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13:1904-1911. DOI: 10.1513/AnnalsATS.201604-246OC

101. Zweijpfenning S., Kops S., Magis-Escurra C., Boeree M.J., van Ingen J., Hoefsloot W. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir Med. 2017;131:220-224. DOI: 10.1016/j.rmed.2017.08.031

102. Peloquin C.A., Berning S.E., Nitta A.T., Simone P.M., Goble M., Huitt G.A., et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:1538-15644. DOI: 10.1086/420742

103. Gordin F.M., Sullam P.M., Shafran S.D., Cohn D.L., Wynne B., Paxton L., et al. A randomized, placebocontrolled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. 1999;28:1080-1085. DOI: 10.1086/514748

104. Cohn D.L., Catlin B.J., Peterson K.L., Judson F.N., Sbarbaro J.A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990;112:407-415. DOI: 10.7326/0003-4819-76-3112-6-407

105. Lam P.K., Griffith D.E., Aksamit T.R., Ruoss S.J., Garay S.M., Daley C.L., et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;173:1283-1289. DOI: 10.1164/rccm.200509-1531OC

106. Wallace R.J. Jr., Brown-Elliott B.A., McNulty S., Philley J.V., Killingley J., Wilson R.W., et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146:276-282. DOI: 10.1378/chest.13-2538

107. Jeong B.H., Jeon K., Park H.Y., Kim S.-Y., Lee K.S., Huh H.J., et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191:96-103. DOI: 10.1164/rccm.201408-1545OC

108. Griffith D.E., Adjemian J., Brown-Elliott B.A., Philley J.V., Prevots D.R., Gaston C., et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;192:754760. DOI: 10.1164/rccm.201503-0444OC

109. van Ingen J., Aksamit T., Andrejak C., Böttger E.C., Cambau E., Daley C.L., et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018;51:1800170. DOI: 10.1183/13993003.001702018

110. Buhler V.B., Pollak A. Human infection with atypical acidfast organisms; report of two cases with pathologic findings. Am J Clin Pathol. 1953;23:363-374. DOI: 10.1093/ajcp/23.4.363

111. Pezzia W., Raleigh J.W., Bailey M.C., Toth E.A., Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis. 1981;3:1035-1039. DOI: 10.1093/clinids/3.5.1035

112. Jenkins D., Bahar D., Chofnas I. Pulmonary disease due to atypical mycobacteria; current concepts. Transactions 19th Conference on Chemotherapy of Tuberculosis. 1960:224231.

113. Ahn C.H., Lowell J.R., Ahn S.S., Ahn S.I., Hurst G.A. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983;128:1048-1050. DOI: 10.1164/arrd.1983.128.6.1048

114. Ahn C.H., Lowell J.R., Ahn S.S., Ahn S., Hurst G.A. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981;3:1028-1034. DOI: 10.1093/clinids/3.5.1028

115. Research Committee, British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax. 1994;49:442-445. DOI: 10.1136/thx.49.5.442

116. Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004;48:4562-4565. DOI: 10.1128/AAC.48.12.4562-4565.2004

117. Guna R., Muñoz C., Domínguez V., García-García A., Gálvez J., de Julián-Ortiz J.-V., et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005;55:950-953. DOI: 10.1093/jac/dki111

118. Brown B.A., Wallace R.J. Jr., Onyi G.O. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother. 1992;36:1987-1990. DOI: 10.1128/aac.36.9.1987

119. Bakula Z., Modrzejewska M., Pennings L., Proboszcz M., Safianowska A., Bielecki J., et al. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii. Antimicrob Agents Chemother. 2018;62:e01788-17. DOI: 10.1128/AAC.01788-17

120. Philley J.V., Griffith D.E. Treatment of slowly growing mycobacteria. Clin Chest Med. 2015;36:79-90. DOI: 10.1016/j.ccm.2014.10.005

121. Harris G.D., Johanson W.G., Nicholson D.P. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. Am Rev Respir Dis. 1975;112:31-36. DOI: 10.1164/arrd.1975.112.1.31

122. Shitrit D., Baum G.L., Priess R., Lavy A., Shitrit A., Raz M., et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129:771-776. DOI: 10.1378/chest.129.3.771

123. Griffith D.E., Brown-Elliott B.A., Wallace R.J. Jr. Thriceweekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37:1178-1182. DOI: 10.1086/378742

124. Santin M., Dorca J., Alcaide F., Gonzalez L., Casas S., Lopez M., et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J. 2009;33:148-152. DOI: 10.1183/09031936.00024008

125. Hornick D.B., Dayton C.S., Bedell G.N., Fick R.B. Jr. Nontuberculous mycobacterial lung disease: substantiation of a less aggressive approach. Chest. 1988;93:550-555. DOI: 10.1378/chest.93.3.550

126. Hombach M., Somoskövi A., Hömke R., Ritter C., Böttger E.C. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. Int J Med Microbiol. 2013;303:270-276. DOI: 10.1016/j.ijmm.2013.04.003

127. Srivastava S., Pasipanodya J., Sherman C.M., Meek C., Leff R., Gumbo T. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Antimicrob Agents Chemother. 2015;59:22732279. DOI: 10.1128/AAC.04441-14

128. Sauret J., Hernández-Flix S., Castro E., Hernández L., Ausina V., Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy. Tuber Lung Dis. 1995;76:104-108. DOI: 10.1016/0962-8479(95)90550-2

129. Jenkins P.A., Banks J., Campbell I.A., Smith A.P. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax. 1994;49:442-445. DOI: 10.1136/thx.49.5.442

130. Shu C.C., Lee C.H., Hsu C.L., Wang J.-T., Wang J.-Y., Yu C.-J., et al.; TAMI Group. Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns. Lung. 2011;189:467474. DOI: 10.1007/s00408-011-9321-4

131. Andréjak C., Lescure F.X., Pukenyte E., Douadi Y., Yazdanpanah Y., Laurans G., et al.; Xenopi Group. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. 2009;64:291-296. DOI: 10.1136/thx.2008.096842

132. Jenkins P.A., Campbell I.A.; Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med. 2003;97:439-444. DOI: 10.1053/rmed.2002.1444

133. Jenkins P.A., Campbell I.A., Banks J., Gelder C.M., Prescott R.J., Smith A.P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63:627-634. DOI: 10.1136/thx.2007.087999

134. Diel R., Ringshausen F., Richter E., Welker L., Schmitz J., Nienhaus A. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest. 2017;152:120-142. DOI: 10.1016/j.chest.2017.04.166

135. Varadi R.G., Marras T.K. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009;13:1210-1218. PMID: 19793424

136. Marras T.K., Campitelli M.A., Lu H., Chung H., Brode S.K., Marchand-Austin A., et al. Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001-2013. Emerg Infect Dis. 2017;23:468-476. DOI: 10.3201/eid2303.161927

137. Andréjak C., Thomsen V.Ø., Johansen I.S., Riis A., Benfield T.L., Duhaut P., et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181:514-521. DOI: 10.1164/rccm.200905-0778OC

138. Schwiesow J.N., Iseman M.D., Peloquin C.A. Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy. 2008;28:1076-1080. DOI: 10.1592/phco.28.8.1076

139. Johnston I.D. Mycobacterium xenopi infection and aspergilloma. Tubercle. 1988;69:139-143. DOI: 10.1016/0041-3879(88)90077-3

140. Carrillo M.C., Patsios D., Wagnetz U., Jamieson F., Marras T.K. Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Can Assoc Radiol J. 2014;65:207-213. DOI: 10.1016/j.carj.2013.05.006

141. Ferro B.E., van Ingen J., Wattenberg M., van Soolingen D., Mouton J.W. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. J Antimicrob Chemother. 2015;70:2838-2843. DOI: 10.1093/jac/dkv180

142. Andréjak C., Almeida D.V., Tyagi S., Converse P.J., Ammerman N.C., Grosset J.H. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother. 2013;68:659-665. DOI: 10.1093/jac/dks421

143. van Ingen J., Hoefsloot W., Mouton J.W., Boeree M.J., van Soolingen D. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. Int J Antimicrob Agents. 2013;42:80-82. DOI: 10.1016/j.ijantimicag.2013.03.010

144. Lounis N., Truffot-Pernot C., Bentoucha A., Robert J., Ji B., Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 2001;45:3229-3230. DOI: 10.1128/AAC.45.11.3229-3230.2001

145. Maurer F.P., Rüegger V., Ritter C., Bloemberg G.V., Böttger E.C. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother. 2012;67:2606-2611. DOI: 10.1093/jac/dks279

146. Tortoli E., Kohl T.A., Brown-Elliott B.A., Trovato A., Leão S.C., Garcia M.J., et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol. 2016;66:4471-4479. DOI: 10.1099/ijsem.0.001376

147. Choi G.E., Shin S.J., Won C.J., Min K.-N., Oh T., Hahn M.-Y., et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186:917-925. DOI: 10.1164/rccm.2011112005OC

148. Park J., Cho J., Lee C.H., Han S.K., Yim J.J. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017;64:301-308. DOI: 10.1093/cid/ciw723

149. Roux A.L., Catherinot E., Soismier N., Heym B., Bellis G., Lemonnier L., et al.; OMA group. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros. 2015;14:63-69. DOI: 10.1016/j.jcf.2014.07.004

150. Lyu J., Kim B.J., Kim B.J., Song J.W., Choi C.-M., Oh Y.-M., et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med. 2014;108:1706-1712. DOI: 10.1016/j.rmed.2014.09.002

151. Wang D., Fu W., Dai J. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Medicine (Baltimore). 2019;98:e15285. DOI: 10.1097/MD.0000000000015285

152. Kelly C., Chalmers J.D., Crossingham I., Relph N., Felix L.M., Evans D.J., et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;3:CD012406. DOI: 10.1002/14651858.CD012406.pub2

153. Aksamit T.R., O’Donnell A.E., Barker A., Olivier K.N., Winthrop K.L., Daniels M.L.A., et al.; Bronchiectasis Research Registry Consortium. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151:982-992. DOI: 10.1016/j.chest.2016.10.055

154. Novosad S.A., .Beekmann S.E., Polgreen P.M., Mackey K., Winthrop K.L.; M. abscessus Study Team. Treatment of Mycobacterium abscessus infection. Emerg Infect Dis. 2016;22:511-514. DOI: 10.3201/eid2203.150828

155. Pasipanodya J.G., Ogbonna D., Ferro B.E., MagombedzeG., Srivastava S., Deshpande D., et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother 2017;61:e01206-17. DOI: 10.1128/AAC.01206-17

156. Nelson K.G., Griffith D.E., Brown B.A., Wallace R.J. Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg. 1998;66:325-330. DOI: 10.1016/s0003-4975(98)00401-9

157. Shiraishi Y., Fukushima K., Komatsu H., Kurashima A. Early pulmonary resection for localized Mycobacterium avium complex disease. Ann Thorac Surg. 1998;66:183-186. DOI: 10.1016/s0003-4975(98)00373-7

158. Shiraishi Y., Nakajima Y., Takasuna K., Hanaoka T., Katsuragi N., Konno H. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg. 2002;21:314-318. DOI: 10.1016/s1010-7940(01)01122-8

159. Watanabe M., Hasegawa N., Ishizaka A., Asakura K., Izumi Y., Eguchi K., et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg. 2006;81:2026-2030. DOI: 10.1016/j.athoracsur.2006.01.031

160. Lang-Lazdunski L., Offredo C., Le Pimpec-Barthes F., Danel C., Dujon A., Riquet M. Pulmonary resection for Mycobacterium xenopi pulmonary infection. Ann Thorac Surg. 2001;72:1877-1882. DOI: 10.1016/s00034975(01)03245-3

161. Koh W.J., Kim Y.H., Kwon O.J., Choi Y.S., Kim K., Shim Y.M., et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci. 2008; 23:397-401. DOI: 10.3346/jkms.2008.23.3.397

162. Yu J.A., Pomerantz M., Bishop A., Weyant M.J., Mitchell J.D. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with nontuberculous mycobacterial disease. Eur J Cardiothorac Surg. 2011;40:671-675. DOI: 10.1016/j.ejcts.2010.12.028

163. Kang H.K., Park H.Y., Kim D., Jeong B.-H., Jeon K., Cho J.H., et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis. 2015;15:76. DOI: 10.1186/s12879015-0823-1

164. Shiraishi Y., Nakajima Y., Katsuragi N., Kurai M., Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg. 2004;78:399403. DOI: 10.1016/j.athoracsur.2004.02.103

165. van Ingen J., Verhagen A.F., Dekhuijzen P.N., van Soolingen D., Magis-Escurra C., Boeree M.J., et al. Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis. 2010;14:99-105. PMID: 20003702

166. Mitchell J.D., Bishop A., Cafaro A., Weyant M.J., Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85:18871892; discussion 92-93. DOI: 10.1016/j.athoracsur.2008.02.041

167. van Ingen J., Egelund E.F., Levin A., Totten S.E., Boeree M.J., Mouton J.W., et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186:559-565. DOI: 10.1164/rccm.2012040682OC

168. Koh W.J., Jeong B.H., Jeon K., Lee S.Y., Shin S.J. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:797-802. DOI: 10.1164/rccm.2012061088OC

169. Magis-Escurra C., Alffenaar J.W., Hoefnagels I., Dekhuijzen P., Boeree M.J., van Ingen J., et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents. 2013;42:256261. DOI: 10.1016/j.ijantimicag.2013.05.007

170. Jeong B.H., Jeon K., Park H.Y., Moon S.M., Kim S.-Y., Lee S.-Y., et al. Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:60766083. DOI: 10.1128/AAC.00770-16

171. Nahid P., Dorman S.E., Alipanah N., Barry P.M., Brozek J.L., Cattamanchi A., et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147-195. DOI: 10.1093/cid/ciw376

Review of the international clinical practice guidelines for the treatment of lung infections caused by nontuberculous mycobacteria

Abstract

Views

Shared

Cited by Crossref